Biosimilar insulins are coming: what they are, what you need to know

References

• Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and insulins. Br J Diabetes Vasc Dis 2010;10:90-7
   Google Scholar
• Heineman L, Hompesch M. Biosimilar insulins: how similar is similar? J Diabetes Sci Tech 2011;5:741-54
   PubMedGoogle Scholar
• Kraümer I, Sauer T. The new world of biosimilars: what diabetologists need to know about biosimilar insulins. Br J Diabetes Vasc Dis 2010;10:163-71
   Google Scholar
• Owens DR, Landgraf L, Schmidt A, et al. The emergence of biosimilar insulin preparations – a cause for concern? Diabetes Tech Ther 2012;14:989-96
   PubMed Web of Science ®Google Scholar
• Home P. Biosimilar. Diabetes Voice 2011;56:40-3
   Google Scholar
• Misra M. Biosimilars: current perspectives and future implications. Ind J Pharmacol 2012;44:12-14
   Google Scholar
• Rotenstein LS, Ran N, Shivers JP, et al. Opportunities and challenges for biosimilars: what’s on the horizon in the global insulin market? Clin Diabetes 2012;30:138-50
   Google Scholar
• Pise S, Pise A. Concept, opportunities and challenges for bio-similar products in healthcare market. IJMPS 2011;1:1-3
   Google Scholar
• US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product (draft guidance). February 2012. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf [Last accessed 6 December 2012]
   Google Scholar
• Nick, C. The US Biosimilars Act: challenges facing regulatory approval. Pharm Med 2012;26:145-52
   Google Scholar
• Drugs@FDA Glossary of Terms. Available at: http://www.fda.gov/Drugs/informationondrugs/ucm079436.htm [Last accessed 6 December 2012]
   Google Scholar
• Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology 2006;11:341-6
   PubMed Web of Science ®Google Scholar
• Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-19
   PubMed Web of Science ®Google Scholar
• Feinglos MN, Thacker CH, English J, et al. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997;20:1539-42
   PubMed Web of Science ®Google Scholar
• Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK insulin aspart study group. Diabetes Care 1998;21:1904-9
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
   PubMed Web of Science ®Google Scholar
• Lee JF, Litten JB Grampp G. Comparability and biosimilarity: considerations for the healthcare provider. Cur Med Res Opin 2012;28:1053-8
   PubMed Web of Science ®Google Scholar
• Biotechnology Industry Organization website. Available at: http://www.bio.org/node/517 [Last accessed 6 December 2012]
   Google Scholar
• Miletich J, Eich G, Grampp G, et al. Biosimilars 2.0: guiding principles for a global ‘patients first’ standard. MAbs 2011;3:318-25
   PubMed Web of Science ®Google Scholar
• Haag-Weber M, Eckardt KU, Hoürl WH, et al. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetina (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 2012;77:8-17
   PubMed Web of Science ®Google Scholar
• Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol 2010;86:277-88
   Web of Science ®Google Scholar
• Schellekens H. Recombinant human erythropoietins, biosimilars and immunogenicity. J Nephrol 2008;21:497-502
   PubMed Web of Science ®Google Scholar
• Schellekens H. Assessing the bioequivalence of biosimilars: the retacrit case. Drug Discov Today 2009;14:495-9
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Roger SD, de Francisco A, et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int 2012;81:727-32
   PubMed Web of Science ®Google Scholar
• Shrank WH, Cox ER, Fischer MA, et al. Patients’ perceptions of generic medications: although most Americans appreciate the cost-saving value of generics, few are eager to use generics themselves. Health Aff (Millwood) 2009;28:546-56
   PubMed Web of Science ®Google Scholar
• Grimberg A, Feudtner C, Gordon CM. Consequences of brand switches during the course of pediatric growth hormone treatment. Endo Pract 2012;18:307-16
   Google Scholar
• AACE, TES, and ATA Joint Position Statement on the Use and Interchangeability of Thyroxine Products. 8 December 2004. Available at: http://www.thyroid.org/thyroxine-products-joint-position-statement/ [Last accessed 24 March 2013]
   Google Scholar
• Lee WC, Balu S, Cobden D, et al. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface 2006;19:31-41
   PubMedGoogle Scholar
• Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24
   PubMed Web of Science ®Google Scholar
• Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836-41
   PubMed Web of Science ®Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab 2012;14:1081-7
   PubMed Web of Science ®Google Scholar
• Karter AJ, Subramanian U, Chandan S, et al. Barriers to insulin initiation: the Translating Research into Action for Diabetes Insulin Starts project. Diabetes Care 2010;33:733-5
   PubMed Web of Science ®Google Scholar
• Haükonsen H, Eilertsen M, Borge H, Toverud E. Generic substitution: an additional challenge for adherence in hypertensive patients? Curr Med Res Opin 2009;25:2515-21
   PubMed Web of Science ®Google Scholar
• Piette JD, Heisler M, Harand A, Julp M. Beliefs about prescription medications among patients with diabetes: variation across racial groups and influences on cost-related medication underuse. J Health Care Poor Underserved 2010;21:349-61
   PubMed Web of Science ®Google Scholar
• Shrank WH, Liberman JN, Fischer MA, et al. Physician perceptions about generic drugs. Ann Pharmacother 2011;45:31-8
   PubMed Web of Science ®Google Scholar